secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001161697-25-000216
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical Q2 revenue up 21% to record $10.2M; raises FY 2025 revenue guidance
--------------------------------------------------------------------------------

- Q2 2025 net revenue of $10.2 million, +21% YoY; Core revenue $9.3M (+19%), PST $0.9M (+42%).
- Adjusted EBITDA positive $0.3M vs ($0.4M) in prior year; net loss narrowed to $0.2M from $1.3M.
- Raises FY 2025 revenue guidance to $39.5-$40.5M (prev. $38.5-$39.5M); gross margin guidance 61%-63% reaffirmed.
- Cash balance $8.1M at Q2-end; reiterated positive operating cash flow for FY 2025.
- Adam Kalbermatten named Chief Commercial Officer; FDA 510(k) submitted for a rare disease biologic drug.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169725000216/0001161697-25-000216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169725000216/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-25-000216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer